Rondo Therapeutics

United States · Founded 2021 · $67.0M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$67.0M
Last Round
$67.0M Series AMar 2022
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Rondo Therapeutics is a clinical-stage biotechnology company developing immune-cell engaging bispecific antibodies that harness the immune system to target and eliminate solid tumors. Its therapies are designed for tumor-selective targeting so they can expand the therapeutic window, eradicate tumors, and protect healthy tissue. Co-founders Shelley Force Aldred and Nathan Trinklein established the company to advance innovative therapeutic antibodies for patients with cancer. The pipeline includes RNDO-564, a CD28 x Nectin-4 program in Phase 1 for bladder cancer and other solid tumors.

Summary

Rondo Therapeutics is a Biotech company based in United States, founded in 2021. It has raised $67.0M in total across 1 round, most recently a $67.0M Series A round in Mar 2022. Investors include Red Tree Venture Capital, Canaan Partners and Novo Holdings A/S.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2022
$67.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Rondo Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/rondo-therapeutics"><img src="https://indexed.vc/api/badge/company/rondo-therapeutics" alt="Rondo Therapeutics on Indexed.vc" width="260" height="76" /></a>